PTC Therapeutics director receives new equity awards
PTC Therapeutics, Inc. director Hege Elisabeth Sollie-Zetlmayer received multiple equity awards on July 28, 2026.
Rhea-AI Filing Summary
PTC Therapeutics, Inc. director Hege Elisabeth Sollie-Zetlmayer received multiple equity awards on July 28, 2026. Grants included 4,000 restricted stock units vesting in three equal annual installments from July 28, 2027, and 2,000 restricted stock units vesting on January 2, 2027. She was also granted stock options for 3,475 and 1,738 shares of common stock at an exercise price of $75.39 per share, vesting over 36 and six equal monthly installments respectively, with both option grants expiring on July 27, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 11,213 shares
Grant/Award
4 txns
Insider
Sollie-Zetlmayer Hege Elisabeth
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F3 | 3,475 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F4 | 1,738 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 4,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock F2 | 2,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,213 contracts (Direct);
Common Stock — 52,526 shares (Direct)
Footnotes (4)
- F1. Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting in three equal annual installments, commencing on July 28, 2027.
- F2. Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting on January 2, 2027.
- F3. This option was granted on July 28, 2026 and vests over 36 equal monthly installments, commencing on August 28, 2026.
- F4. This option was granted on July 28, 2026 and vests over six equal monthly installments, commencing on August 2, 2026.
Key Figures
RSU Grant 1: 4,000 shares
RSU Grant 2: 2,000 shares
Stock Option Grant 1: 3,475 shares at $75.39
+2 more
5 metrics
RSU Grant 1
4,000 shares
Restricted stock units vesting in three equal annual installments from July 28, 2027
RSU Grant 2
2,000 shares
Restricted stock units vesting on January 2, 2027
Stock Option Grant 1
3,475 shares at $75.39
Option vesting over 36 equal monthly installments from August 28, 2026; expires July 27, 2036
Stock Option Grant 2
1,738 shares at $75.39
Option vesting over six equal monthly installments from August 2, 2026; expires July 27, 2036
Transaction Date
July 28, 2026
Grant date for all reported RSU and stock option awards
Key Terms
Restricted stock units, Stock Option (Right to Buy), exercise price, vesting
4 terms
Restricted stock units financial
"Restricted stock units granted on July 28, 2026, with the shares underlying"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price": "75.3900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"vests over 36 equal monthly installments, commencing on August 28, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did PTC Therapeutics (PTCT) grant to Hege Elisabeth Sollie-Zetlmayer?
PTC Therapeutics granted Hege Elisabeth Sollie-Zetlmayer 6,000 shares of common stock via restricted stock units and 5,213 shares via stock options. These awards were all granted on July 28, 2026 as part of her equity compensation package.
How do the restricted stock units for PTCT vest for Hege Elisabeth Sollie-Zetlmayer?
One RSU grant of 4,000 shares vests in three equal annual installments starting July 28, 2027. A second RSU grant of 2,000 shares vests in full on January 2, 2027, providing both long-term and near-term equity vesting schedules.
What are the terms of the stock options granted by PTCT to its director?
Sollie-Zetlmayer received stock options for 3,475 and 1,738 shares of common stock with an exercise price of $75.39 per share. Both option grants expire on July 27, 2036, giving a long exercise window.
What are the vesting schedules for the PTCT stock options granted on July 28, 2026?
The 3,475-share option grant vests over 36 equal monthly installments starting August 28, 2026. The 1,738-share option grant vests over six equal monthly installments starting August 2, 2026, creating staggered short- and medium-term vesting.
Is the PTCT Form 4 transaction a purchase or a grant for the director?
The Form 4 reports grants, not market purchases. All four transactions are coded as awards or other acquisitions (Code A), reflecting equity compensation in the form of restricted stock units and stock options, rather than open-market buying.
Does the PTCT director’s Form 4 involve any stock sales or dispositions?
No. All reported transactions are acquisitions of equity awards. The filing shows grants of restricted stock units and stock options, with no sales, gifts, or other dispositions reported for the July 28, 2026 transaction date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
